Hatzipanagiotou, Maria Eleni http://orcid.org/0000-0003-2831-4282
Pigerl, Miriam
Gerken, Michael
Räpple, Sophie
Zeltner, Verena
Hetterich, Madeleine
Ugocsai, Peter
Fernandez-Pacheco, Miriam
Inwald, Elisabeth Christine
Klinkhammer-Schalke, Monika
Ortmann, Olaf
Seitz, Stephan
Funding for this research was provided by:
Universitätsklinikum Regensburg
Article History
Received: 7 June 2023
Accepted: 28 June 2023
First Online: 7 July 2023
Declarations
:
: Miriam Pigerl, Sophie Räpple, Verena Zeltner, Peter Ugocsai, Elisabeth Inwald, Michael Gerken, Miriam Fernandez and Monika Klinkhammer-Schalke declare they have no financial interests. Maria Hatzipanagiotou has received Honoraria for lectures and/or consulting from Novartis, Lilly, Roche, Pfizer and AstraZeneca. Madeleine Hetterich has received speaker honoraria from Celgene, Novartis, MSD, GSK. Eisai and AstraZeneca as well as author honoraria from Thieme and Elsevier and travel reimbursement from Novartis. Olaf Ortmann is on the board of the German Cancer society. He received speaker honoraria from MSD SHARP & DOHME GMBH. Verband Forschender Arzneimittelhersteller vfa, Novo Nordisk, AstraZeneca, Aurikamed, Med Update, RG Ärztefortbildung, Pierre Fabre Pharma GmbH and holds stocks from Bayer, Novartis, Curevac and Fresenius. Stephan Seitz has received speaker honoraria from AstraZeneca, GE, GSK, IGEA, Lilly, MSD, Novartis, Pfizer, Roche and honoraria for consulting from AstraZeneca, GSK, Lilly, MSD, Novartis, Pfizer and Roche.
: This study was carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki). All members of the research team committed themselves to the confidentiality of the information provided as well as to data protection and are subject to medical confidentiality.